Are you Dr. McGowan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 43 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 Ridgeview Dr
Horsham, PA 19044Phone+1 215-325-5329- Is this information wrong?
Summary
- Dr. Tracy McGowan, MD is a nephrologist in Horsham, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Nephrology, 1996 - 1999- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1992 - 1995
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1992
Certifications & Licensure
PA State Medical License 1993 - 2024
Publications & Presentations
PubMed
- 11 citationsAn Open-Label, Randomized, Multicenter, Controlled Study of Epoetin Alfa for the Treatment of Anemia of Chronic Kidney Disease in the Long Term Care SettingMeenakshi Patel, David G. Thimons, Jaron L. Winston, Wayne Langholff, Tracy A. McGowan> ;Journal of the American Medical Directors Association. 2012 Mar 1
- 210 citationsPirfenidone for Diabetic NephropathyKumar Sharma, Joachim H. Ix, Anna V. Mathew, Monique E. Cho, Axel Pflueger, Stephen R. Dunn, Barbara B. Francos, Shoba Sharma, Bonita Falkner, Tracy A. McGowan, Michae...> ;Journal of the American Society of Nephrology. 2011 Jun 1
- 129 citationsPirfenidone Is Renoprotective in Diabetic Kidney DiseaseSatish P. RamachandraRao, Yanqing Zhu, Timothy Ravasi, Tracy A. McGowan, Irene Toh, Stephen R. Dunn, Shinichi Okada, Michael A. Shaw, Kumar Sharma> ;Journal of the American Society of Nephrology. 2009 Aug 1
- Join now to see all
Press Mentions
New ERLEADA® (Apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)February 14th, 2022- (Apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence RatesSeptember 12th, 2021
